Stephen V Liu: Editorial New England Journal of Medicine from Dr. Christine Lovly, gives nice perspective on the phase III KEYNOTE 671 study in resectable non-small-cell lung cancer

As per Stephen V. Liu, the Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, in a tweet, he mentions that the “Editorial New England Journal of Medicine from Dr. Christine Lovly, gives nice perspective on the phase III KEYNOTE 671 study in resectable NSCLC. Perioperative immunotherapy provides clear benefit but many ?s remain – especially regarding the need to continue IO and an MRD test.”

For the article: click here
Source: Stephen V Liu / Twitter